Oncology

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

A new alliance between Sun Life and Medzown moves beyond financial safety nets, using AI to steer patients to clinical trials and reshape corporate healthcare.

A landmark court ruling forces a recall of Siemens' latest mammography tech, handing Hologic a major victory and sending shockwaves through Europe's MedTech.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

Komodo Health restructures its C-suite, signaling a major shift in healthcare. It's no longer about AI hype; it's about enterprise-scale dominance.

A new manufacturing patent for pelareorep de-risks Oncolytics' path to market, protecting the drug until 2044 and signaling commercial readiness.

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.

Ice Cube's BIG3 league and the PCF are deploying a new playbook, using basketball's cultural power to bring life-saving cancer screenings directly to Black men.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

A new corporate alliance is targeting veteran lung disease. It’s more than a webinar; it’s a strategic response to the PACT Act’s seismic shift.

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

Arima Genomics' award-winning Aventa test is revolutionizing lymphoma diagnostics by seeing cancer in 3D, moving beyond 2D methods to find what others miss.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Apollo Athenaa's new handbook addresses caregiver burnout, offering a vital resource to the unsung heroes of India's growing cancer crisis.